Ann: Phase 1B CHM CORE-NK trial advances to newly diagnosed AML, page-11

PS: Would investigators be allowed to use a therapy such as CORE-NK on newly diagnosed patients if there was going to be any possibility of toxicity? Not a chance.... so, that box has been ticked! Now its all about efficacy and, probably most importantly, duration of efficacy.

The awareness around immunotherapy is growing rapidly. Mainstream is learning about it, and I believe that a lot more people being diagnosed with cancer are asking about immunotherapies. I know if I were diagnosed with cancer in my latter years, I'd say, "You can stick chemo.. I'm not having it!" and opt for the less invasive drug and preferably immunotherapy. Quality of life is just as important as quantity for some people. Its a growing market... and CORE-NK is only just starting with AML here.